

1 **SUPPLEMENTARY INFORMATION**

2

3 **Impact of dietary resistant starch type 4 on human gut microbiota and immunometabolic**
4 **functions**

5 Bijaya Upadhyaya¹, Lacey McCormack^{1#}, Ali Reza Fardin-Kia^{2#}, Robert Juenemann^{1#},
6 Sailendra Nichenametla¹, Jeffrey Clapper³, Bonny Specker⁴, and Moul Dey^{1*}

7

8 ¹Health and Nutritional Sciences, South Dakota State University, Box 2203, Brookings, SD
9 57007, USA

10 ²Office of Regulatory Science, Center for Food Safety and Applied Nutrition, HFS-717, US
11 Food and Drug Administration, College Park, MD 20740, USA

12 ³Department of Animal Science, South Dakota State University, Box 2170, Brookings, SD
13 57007, USA

14 ⁴Ethel Austin Martin Program in Human Nutrition, South Dakota State University, Box 506,
15 Brookings, SD 57007, USA

16

17 # Equal contributors

18 * Corresponding author

19

20 This file contains additional methods, figures and tables.

21 **Materials and Methods (Supplementary Information)**

22 Subjects

23 Participants in this study included a subset of the parent cohort consisting of 20 individuals who
24 originally participated in a dietary intervention with RS4¹. Briefly, this study was conducted in
25 an adult population, consisting of both males and females, from two Hutterite colonies in eastern
26 South Dakota, USA. The Hutterites are a culturally homogeneous Caucasian population of
27 Central European ancestry. The parent trial is registered in clinicaltrials.gov (NCT01887964).
28 From 40 participants who had signs of metabolic syndrome at baseline, 26 subjects submitted
29 stool samples at all four data collection time points. Out of 26, 20 subjects (10 from each of the
30 two colonies) were included in the current investigation as their faecal samples were adequate to
31 carry out both sequencing and short chain fatty acid (SCFA) analyses (Fig. 1). The selected
32 cohort included 12 females and eight males, aged 32-77 (Supplementary Table S1). Exclusion
33 criteria included pregnancy, lactation, long-term antibiotic therapy, immune compromised state,
34 cancer, and other conditions that would affect the ability to provide informed consent or comply
35 with the protocol.

36

37 Test Diets

38 Participants consumed control flour (CF) and resistant starch type 4(RS4) flours as described in
39 Nichenametla *et al.*¹. RS4 flour was made by substituting 30% (v/v) of the CF with RS4
40 (Fibersym RW, MGP Ingredients Inc., Atchison, KS). The sequence of flour consumption was
41 randomly assigned to the colonies. Dietary intake was assessed by using a 3-day (2 weekdays
42 and 1 weekend day) semi-quantitative food-frequency questionnaire, customized to include
43 foods that Hutterites frequently consume, mostly consisting of items cooked from raw

44 ingredients. Evidence show that the Hutterites consume more fresh produce in summer and
45 preserved or frozen food in winter resulting into a diet-influenced shifts in microbiome ². Since
46 the study period did not overlap with winter months, the impact of seasonal variation on gut
47 microbiome was not considered. Diet analysis was performed using Nutritionist Pro (Axxya
48 Systems, Redmond, WA, USA) to obtain macro-nutrient breakdown of the consumed diets.

49

50 Study design:

51 The original trial ¹ was conducted as a two-period, total 26-week long double blind (participants–
52 investigators), placebo-controlled, cluster cross-over intervention (Fig. 1a). Each intervention
53 period (CF and RS4) was for 12 weeks with a washout time of two weeks in between. All data
54 and bio specimens were collected on-site from both colonies at baseline, 12, 14, and 26 weeks
55 except body composition analyses, which were carried out at baseline, 12 and 26 weeks. A
56 modified CONSORT flow chart is provided (Fig. 1b). The study was conducted under free-
57 living conditions, and no dietary restrictions were imposed. Gastrointestinal symptoms and stool
58 consistency were scored based on a one-on-one interview with the participants ¹. Current and
59 past medical information were obtained at each visit which included medication or dietary
60 supplement use, menopausal status, medical conditions, and hospital stays. Seven-day physical
61 activity-recall questionnaires were administered by trained staff to assess any atypical physical
62 activity.

63

64 Anthropometric measurements

65 Height, weight, waist circumference, and blood pressure were measured at the beginning and at
66 the end of each intervention period following standard procedures that were previously described

67 ³. Briefly, height was determined using a stadiometer and recorded to the nearest 0.5 cm. Body
68 weight was measured on an electronic scale (Seca GmbH & Co., Hamburg, Germany) with the
69 subjects in light clothes and no shoes and was recorded to the nearest 0.1 kg. Waist
70 circumference was measured at the navel using a tension-sensitive, non-stretching Gulick tape
71 and recorded to the nearest 0.5 cm. Blood pressure was measured with a digital
72 sphygmomanometer in a sitting position. Body composition (fat mass and fat-free mass) was
73 determined by total-body, dual-energy, x-ray absorptiometry (DXA) scanning (Hologic QDR
74 Discovery A, Waltham, MA) as described previously ⁴. Fat mass is presented as % body fat in
75 paper.

76

77 Blood biochemistry

78 Overnight fasting blood was collected by venepuncture in vacutainer tubes (BD Biosciences,
79 Franklin Lakes, NJ). Fasting blood glucose, total cholesterol (TC), Low-Density-Lipoprotein
80 cholesterol (LDL), High-density-Lipoprotein cholesterol (HDL), non-HDL cholesterol (non-
81 HDL), triglycerides were determined using the Cholestech LDX point-of-care analyzer (Alere
82 Inc, Waltham, MA), lipid profile and glucose cassettes (Lipid Profile GLU, Alere Inc, Waltham,
83 MA), following the manufacturers' instructions. Postprandial glucose was determined 2 h after
84 either breakfast or the noon meal by using a FreeStyle Freedom Lite blood glucose meter
85 (Abbott Diabetes Care Inc, Alameda, CA), following the manufacturer's instructions.

86 Participants typically consumed a food item made with test flour during the meal prior to the
87 postprandial glucose test. Glycosylated haemoglobin (HbA1C) was determined by an enzyme-
88 based colorimetric assay using the Human HbA1C kit (Crystal Chem, Downers Grove, IL),
89 following the manufacturer's instructions. Each sample was run in duplicate, and a batch control

90 was used to account for inter-assay variation. HbA1C levels were expressed as the percentage of
91 total haemoglobin. Two markers of inflammation, interleukin 6 (IL6) and tissue necrotic factor- α
92 were determined (in duplicate) in serum using Human ELISA Ready-SET-Go kits, following the
93 manufacturer's instructions (eBioscience, San Diego, CA). Plasma adiponectin levels, an
94 indicator of metabolic functions, were detected by Human Adiponectin Radioimmunoassay
95 following the manufacturer's instructions (Linco Research, St. Charles, MO). Inter- and Intra-
96 assay coefficients of variance were 5.0% and 11.7%, respectively.

97

98 Faecal SCFA analysis by gas chromatography-mass spectrometry (GC-MS)

99 To prepare faecal samples for SCFA analyses, 800-1000 mg faecal sample was homogenized and
100 added to a glass tube containing 1 ml of internal standard (2-ethylbutyric acid in 1-butanol, 1
101 mg/mL). Organic solvent hexane and derivatizing agents, hydrogen chloride 1-butanol or Boron
102 trifluoride 1-butanol (both from Sigma-Aldrich, St. Louis, MO), were then added with vortexing
103 between each addition. Boron trifluoride 1-butanol and hydrogen chloride 1-butanol were used to
104 create butyl-esters for SCFA detection. Samples were then sonicated and placed in water bath
105 (90-100 °C) for 1h. Once cooled to room temperature, water and additional hexane were added to
106 the samples and centrifuged at 3000g for two min. The organic layer (~2 mL) was transferred
107 into a sampling vial with 150 μ L inserts, finally adding a pinch (~10 mg) of anhydrous sodium
108 sulphate to remove the residual water. Faecal extracts were stored at -20 °C until further analysis.

109

110 GC-MS analyses were performed with an GC-MS 5977A (Agilent Technologies, Wilmington,
111 DE, USA) and an HP-5MS UI capillary column (30 m x 0.25mm, 0.2 μ m thickness, Agilent,
112 Wilmington, DE, USA). Hydrogen was used as carrier gas at 1.9 mL/min constant flow and a

113 typical injection volume was 1 μ L in the split mode (1:10). The separation of SCFA butyl esters
114 was achieved using an oven temperature program as follow: initial elution temperature was 55 $^{\circ}$ C
115 for 4 min then 5 $^{\circ}$ C/min to 120 $^{\circ}$ C and then 20 $^{\circ}$ C/min to 220 $^{\circ}$ C for 10 min. The selective mass
116 detector was operated in the 'single ion monitoring and scan' (SIM/Scan) mode. The source was
117 maintained at 150 $^{\circ}$ C and the electron energy was 70 eV.

118

119 Community structure analysis of gut microbes

120 Stool DNA was extracted using the QIAamp DNA Stool Mini Kit (QIAGEN, Valencia, CA)
121 according to the manufacturer's instructions. All samples were quantified via the Qubit[®] Quant-
122 iT dsDNA Broad-Range Kit (Invitrogen, Life Technologies, Grand Island, NY). Sample DNAs
123 were sent to Second Genome (South San Francisco, CA) for metagenome sequencing, and
124 operational taxonomic unit (OTU) identification. Briefly, samples were enriched for bacterial
125 16S V4 rDNA region, DNA was amplified utilizing fusion primer designed against the Illumina
126 (San Diego, CA) flow cell adapters and indexing barcodes. Each sample was PCR-amplified
127 with two differently bar coded V4 fusion primers. For each sample, amplified products were
128 concentrated using a solid-phase reversible immobilization method for the purification of PCR
129 products and quantified by electrophoresis using an Agilent 2100 Bioanalyzer[®] (Agilent
130 Technologies, Santa Clara, CA). Sequencing was carried out using Illumina MiSeq platform
131 following standard protocols for 250 cycles with custom primers designed for paired-end
132 sequencing. Using Quantitative Insights Into Microbial Ecology or QIIME ⁵ and generated
133 custom scripts (Second Genome), sequences were quality-checked and demultiplexed to
134 determine exact matches to the supplied DNA barcodes. Resulting sequences were then searched
135 against the Greengenes reference database of 16S rRNA gene sequences, clustered at 97% by

136 uclust (closed reference OTU picking). The longest sequence from each OTU was then assigned
137 taxonomic classification via Mothur's Bayesian classifier, trained against the Greengenes
138 database clustered at 98%. For unidentified Greengenes OTUs, we cross referenced with closest
139 hits from NCBI 16S rRNA database with query cover (>90%), identity (>87%), and E value
140 (<0.01).

141

142 Statistical analyses

143 Data analyses were performed using two approaches. Effects of CF and RS4 interventions were
144 determined by comparing end-point data, while effects of RS4 intervention alone was presented
145 by comparing the data before and after RS4 intervention. Linear mixed effects models (SAS
146 MIXED procedure) were used to compare the effects of RS4 and CF on biological parameters.
147 All models included variables for colony and season, where colony was a surrogate for
148 randomization sequence and season was a surrogate for crossover treatment period. Because the
149 crossover design used only two clusters (colonies), and any carryover effect might be
150 confounded by cluster sampling effect (colony effects), thus a carryover effect could not be
151 independently evaluated in the mixed models. Covariates for age, sex, baseline value of the
152 outcome variable, change in total calorie intake were evaluated for their association with the
153 response variables, and covariates that significantly affected at least one outcome variable were
154 retained in the final model as fixed effects. The final models included season, colony, sex, age,
155 and initial baseline value of the response variable as fixed effects.

156

157 When appropriate data were presented for either all-participants or stratifying participants based
158 on missing data or outliers in microbial changes as our observations concur with a prior report of

159 large inter-subject variations in response to RS4 ⁶. For microbiome analyses one subject was
160 excluded (n=19) because of *Lactobacillus* probiotic supplement use during the RS4 intervention
161 period. For multivariate analysis PhyCA-Stats™ software package (Second Genome Inc, South
162 San Francisco, CA) was utilized. Differences in the bacterial taxa and host phenotypes among
163 time points were determined by paired t-test or student's t-test as appropriate. If the data were
164 not normally distributed, values were subjected to logarithmic transformations as indicated.

165
166 Two approaches for sampling normalization were employed to account for uneven sequencing
167 depth during data analyses on metagenome sequencing. First, taxa were filtered to those present
168 in at least one of the samples, selecting 55,079 sequences from each sample before calculating
169 community-wide dissimilarity measures. This facilitated calculations of microbial relative
170 abundances (Fig. 3b, 4b, 5, 6, and Supplementary Fig. S1), and principal coordinate analyses
171 (Fig. 2). Second, the samples were normalized to 1 million counts. Thus the shift in microbial
172 profile between the samples or groups was calculated based on per million sequences, which
173 facilitated calculations of 71 differentially abundant OTUs (Supplementary Table S2) or species
174 (Fig. 3a and 3c).

175
176 We used various R-packages (<http://www.r-project.org/>) for downstream data analyses on gut
177 microbiome. Package edgeR
178 (<http://www.bioconductor.org/packages/release/bioc/html/edgeR.html>) ⁷ which has the distinct
179 benefit of increasing the sensitivity of detecting differentially abundant features, was utilized to
180 control for inter-subject variability because of a model-based normalization to adjust for varying
181 sequencing depths. This approach of identifying differentially abundant taxa between treatments

182 borrows from the RNA sequencing literature testing for differential gene expression. These
183 methods have recently been demonstrated to effectively translate to microbiome analyses ⁸,
184 offering a robust method with options for paired sample comparisons even for experiments with
185 minimal levels of biological replication. To correct for multiple comparisons, a false discovery
186 rate correction was used to correct for *p*-values (adjusted *p* is represented as *q*). In order to
187 generate correlation matrices and heat maps, several R-packages, namely Hmisc
188 (<http://CRAN.R-project.org/package=Hmisc>) ⁹, corrplot ([http://CRAN.R-](http://CRAN.R-project.org/package=corrplot)
189 [project.org/package=corrplot](http://CRAN.R-project.org/package=corrplot)) ¹⁰, gplots (<http://CRAN.R-project.org/package=gplots>) ¹¹, and
190 ecodist (<https://CRAN.R-project.org/package=ecodist>) ¹² were used. Significant variation in
191 microbiome baseline values between intervention-groups were ruled out using a Permutational
192 Multivariate Analysis of Variance that also confirmed the effectiveness of the washout period.
193 Two-dimensional Principal Coordinate Analysis (PCoA) followed by Adonis test was used for
194 plotting dissimilarity values so that the similar data points get closer to each other. Statistical
195 analyses were carried out using Sigma Plot software (Systat Software, Inc., San Jose, CA) and
196 the data were presented as means±S.E.M, unless otherwise noted. A *p* value of 0.05 or less was
197 considered significant, while a *p* value of 0.05 to 0.09 was considered trend or approaching
198 significance.

199 **References Cited in the Supplementary Information**

- 200 1 Nichenametla, S. N. *et al.* Resistant starch type 4-enriched diet lowered blood cholesterol and
201 improved body composition in a double blind controlled cross-over intervention. *Mol Nutr Food*
202 *Res* **58**, 1365-1369, doi:10.1002/mnfr.201300829 (2014).
203
- 204 2 Davenport, E. R. *et al.* Seasonal variation in human gut microbiome composition. *PLoS One* **9**,
205 e90731, doi:10.1371/journal.pone.0090731 (2014).
206
- 207 3 Wey, H. E., Binkley, T. L., Beare, T. M., Wey, C. L. & Specker, B. L. Cross-sectional versus
208 longitudinal associations of lean and fat mass with pqt bone outcomes in children. *J Clin*
209 *Endocrinol Metab* **96**, 106-114, doi:10.1210/jc.2010-0889 (2011).
210
- 211 4 Wosje, K. S., Binkley, T. L., Fahrenwald, N. L. & Specker, B. L. High bone mass in a female
212 hutterite population. *J Bone Miner Res* **15**, 1429-1436, doi:10.1359/jbmr.2000.15.8.1429 (2000).
213
- 214 5 Caporaso, J. G. *et al.* Qiime allows analysis of high-throughput community sequencing data. *Nat*
215 *Methods* **7**, 335-336, doi:10.1038/nmeth.f.303 (2010).
216
- 217 6 Martinez, I., Kim, J., Duffy, P. R., Schlegel, V. L. & Walter, J. Resistant starches types 2 and 4
218 have differential effects on the composition of the fecal microbiota in human subjects. *PLoS One*
219 **5**, e15046, doi:10.1371/journal.pone.0015046 (2010).
220
- 221 7 Robinson, M. D., McCarthy, D. J. & Smyth, G. K. Edger: A bioconductor package for differential
222 expression analysis of digital gene expression data. *Bioinformatics* **26**, 139-140,
223 doi:10.1093/bioinformatics/btp616 (2010).

224

225 8 McMurdie, P. J. & Holmes, S. Waste not, want not: Why rarefying microbiome data is
226 inadmissible. *PLoS Comput Biol* **10**, e1003531, doi:10.1371/journal.pcbi.1003531 (2014).

227

228 9 Harrell Jr, F. E. & Dupont, C. Hmisc: Harrell miscellaneous. R package version 3.17-0. (2015).

229

230 10 Wei, T. Corrplot: Visualization of a correlation matrix. R package version 0.73. (2013).

231

232 11 Warnes, G. R. *et al.* Gplots: Various r programming tools for plotting data. R package version
233 2.17.0. (2015).

234

235 12 Goslee, S. C. & Urban, D. L. The ecodist package for dissimilarity-based analysis of ecological
236 data. *J Stat Softw* **22**, 1-19 (2007).

237

238 **Supplementary Table S1. Baseline**
 239 **characteristics of 20 participants**

Criteria	<i>n</i>
<i>Age (years)</i>	
<50	5
≥50	15
<i>BMI</i>	
<30	5
≥30	15
<i>Gender</i>	
Male	8
Female	12
<i>Medication for</i>	
No medication	8
Type 2 diabetes	4
Heart diseases	2
Blood pressure	11
Fibre supplement	2
Probiotic supplement	1
Digestive support	3
Cholesterol lowering	5

240

241 *n*: number of individuals

242 BMI: body mass index

243

244

245 **Supplementary Table S2: 71 differentially modulated operational taxonomic units (OTUs)**
 246 **after RS4 intervention compared to CF control (a separate Excel file)**


247 **Figures and Legends**

248

249 **Supplementary Figure S1. Phylum-level gut microbial composition of participants at**
250 **baseline.** Mean percentage of total bacteria in the major phyla (n=19).

251


252



253


254

255 **Supplementary Figure S2: Representative chromatogram showing separation of the butyl**
256 **esters of SCFA fragment in a baseline sample.** Butyl esters of SCFAs, acetic acid (1),
257 propionic acid (2), iso-butyric acid (3), butyric acid (4), iso-valeric acid (5), valeric acid (6),
258 internal standard (7), and hexanoic acid (8) clearly separated out long chain saturated fatty acid-
259 and mono-unsaturated fatty acid-esters (9). * represents the di-butyl ether as a by product of
260 butylation that did not co-elute with the sample analytes. Samples were run using Scan/SIM
261 mode; the SIM mode facilitated quantification and the scan mode was used for screening and
262 visualization.



263

264 **Supplementary Figure S3. Associations among host biological parameters in the RS4**
 265 **group.** Heat map showing Pearson's r values, corresponding to the size of the circle (n=13, * $p \leq$
 266 0.05, ** $p \leq 0.01$, *** $p \leq 0.001$).



267